Shane Olwill - Pieris Pharmaceuticals Senior Officer
| PIRS Stock | USD 16.25 0.58 3.45% |
Executive
Shane Olwill is Senior Officer of Pieris Pharmaceuticals
| Age | 48 |
| Address | 225 Franklin Street, Boston, MA, United States, 02110 |
| Phone | 857 246 8998 |
| Web | https://www.pieris.com |
Shane Olwill Latest Insider Activity
Tracking and analyzing the buying and selling activities of Shane Olwill against Pieris Pharmaceuticals stock is an integral part of due diligence when investing in Pieris Pharmaceuticals. Shane Olwill insider activity provides valuable insight into whether Pieris Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Pieris Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Pieris Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Shane Olwill over six months ago Acquisition by Shane Olwill of 215819 shares of Pieris Pharmaceuticals at 3.03 subject to Rule 16b-3 |
Pieris Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.1318) % which means that it has lost $0.1318 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8046) %, meaning that it created substantial loss on money invested by shareholders. Pieris Pharmaceuticals' management efficiency ratios could be used to measure how well Pieris Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.67 in 2024. Return On Capital Employed is likely to drop to -1.17 in 2024. At this time, Pieris Pharmaceuticals' Other Assets are comparatively stable compared to the past year. Other Current Assets is likely to gain to about 12.3 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 13.5 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Dennis Williams | Adaptimmune Therapeutics Plc | N/A | |
| Robert Arbeit | X4 Pharmaceuticals | 76 | |
| MD BA | Adaptimmune Therapeutics Plc | 60 | |
| Leiv Lea | Corvus Pharmaceuticals | 70 | |
| Diana Chung | Terns Pharmaceuticals | N/A | |
| John Lunger | Adaptimmune Therapeutics Plc | 54 | |
| BA ACA | Adaptimmune Therapeutics Plc | 54 | |
| Pharm MPH | X4 Pharmaceuticals | N/A | |
| Melita Jung | Terns Pharmaceuticals | 47 | |
| Kerry Sharp | Adaptimmune Therapeutics Plc | N/A | |
| Kirk MD | PDS Biotechnology Corp | 72 | |
| Arndt MD | Affimed NV | 58 | |
| Cintia PharmD | Adaptimmune Therapeutics Plc | 50 | |
| Dana Lynch | Adaptimmune Therapeutics Plc | N/A | |
| Deanne Randolph | PDS Biotechnology Corp | N/A | |
| Suba Krishnan | Mereo BioPharma Group | 59 | |
| Mohamed MD | ADC Therapeutics SA | 59 | |
| Stephanie Fagan | Agenus Inc | N/A | |
| Lisa Kallebo | ADC Therapeutics SA | N/A | |
| Tariq Ahmed | Achilles Therapeutics PLC | N/A | |
| Sanjay Zaveri | PDS Biotechnology Corp | N/A | |
Management Performance
| Return On Equity | -0.8 | ||||
| Return On Asset | -0.13 |
Pieris Pharmaceuticals Leadership Team
Elected by the shareholders, the Pieris Pharmaceuticals' board of directors comprises two types of representatives: Pieris Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Pieris. The board's role is to monitor Pieris Pharmaceuticals' management team and ensure that shareholders' interests are well served. Pieris Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Pieris Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Maria Kelman, Executive Relations | ||
| Thomas Bures, Senior CFO | ||
| Prompong Chaikul, Chief Officer | ||
| Ahmed JD, Chief VP | ||
| Gordon MD, Head Oncology | ||
| Stephen JD, President CEO | ||
| Florian Witte, VP Leadership | ||
| Christine Rothe, VP Science | ||
| Hitto Kaufmann, VP Officer | ||
| Frank Vollmering, Vice Resources | ||
| Shane Olwill, Senior Officer |
Pieris Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Pieris Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.8 | ||||
| Return On Asset | -0.13 | ||||
| Profit Margin | (1.14) % | ||||
| Operating Margin | (0.57) % | ||||
| Current Valuation | (4.15 M) | ||||
| Shares Outstanding | 1.32 M | ||||
| Shares Owned By Insiders | 0.06 % | ||||
| Shares Owned By Institutions | 52.92 % | ||||
| Number Of Shares Shorted | 25.45 K | ||||
| Price To Earning | (6.95) X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Pieris Stock Analysis
When running Pieris Pharmaceuticals' price analysis, check to measure Pieris Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pieris Pharmaceuticals is operating at the current time. Most of Pieris Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Pieris Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pieris Pharmaceuticals' price. Additionally, you may evaluate how the addition of Pieris Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.